Record Q1 revenue of $62.8M, up 20% YoY; net loss narrows to $0.16/share

Cryoport, Inc.

2023-Q1 EPS reported -$0.16 revenue$62,817,000

Revenue $62.8M, +20% YoY (+23% constant currency); Biopharma/Pharma +19%, Animal Health +30%, Reproductive Medicine +13%.
Net loss attributable to common stockholders $7.6M ($0.16/share) vs $15.4M ($0.31) YoY; adjusted EBITDA $2.9M vs $2.0M.
Commercial cell and gene therapy revenue +28% YoY; supports 652 clinical trials (82 Phase 3) and 10 commercial therapies.
Cash and short-term investments $522.6M; FY 2023 revenue guidance reaffirmed at $270-290M.
New partnerships with Syneos Health (jan 2023), Inception Fertility (Mar 2023), and Boston IVF (Apr 2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the first quarter ended March 31, 2023 results: revenue $62.8 million.

Period: the first quarter ended March 31, 2023
Revenue: $62.8 million
Result: reported results

Exact text from the filing

We are pleased to report that we delivered record revenue of $62.8 million for the first quarter

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-056041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.